Member Info for Croasdalelfc

We rns

The B shares will be in the form of a Dividend and then cancelled or have no voting rights. They will be issued on the 5th and ex dividend on the 14th . So will be paid by then. Where shareholders elect for an income receipt a dividend is usually declared on the B shares equal to the amount of value to be returned. After the dividend has been paid the B shares automatically convert into deferred shares with limited rights and negligible value which can be repurchased by the company (or redeemed provided the B shares were not created from non redeemable shares). The dividend has to be paid from the company�s distributable reserves. Also the stock should refloat on AIM next week according to Malcy

How is the cash returned to Shareholders? Once the B Shares are created, Shareholders are often given three options an income option, a immediate capital option and a deferred capital option. The amount of cash they receive will be the same under each option so the dividend paid on the B shares will be the same as the amount for the redemption or repurchase of the shares. Income Option Where shareholders elect for an income receipt a dividend is usually declared on the B shares equal to the amount of value to be returned. After the dividend has been paid the B shares automatically convert into deferred shares with limited rights and negligible value which can be repurchased by the company (or redeemed provided the B shares were not created from non redeemable shares). The dividend has to be paid from the company�s distributable reserves. Under the Companies Act 2006, the company may only make a distribution out of profits available for that purpose. Immediate Capital Option Where shareholders elect for this option, they receive a payment for their shares and these are either repurchased or redeemed by the company. They can only be redeemed if they were issued as redeemable shares. In addition, to ensure the redemption is treated as a capital payment: the B shares must be issued by way of a bonus issue out of share premium account and not from any income type reserve (which may include a capital redemption reserve); and the nominal value of the redeemable shares created must be equal to the aggregate amount of cash being returned as any redemption at a premium will give rise to an income distribution. In addition redeemable shares can only be redeemed by public companies out of distributable profits or proceeds of a fresh issue of shares. The advantage of redemption over repurchase for the company is that it will not have to pay stamp duty on the value of the B shares redeemed. Where there are insufficient reserve to create shares with an aggregate nominal value equal to the amount to be returned, a bonus issue can be used to create B shares with a low nominal value which are then purchased by the company�s broker or principal who on-sells them to the company. Provided the broker is acting as principal and acquire beneficial ownership of the shares, the sale will usually constitute a capital gains disposal.

A B Share Scheme is one method used by UK companies to return excess capital to shareholders. It gives shareholders a choice over the form the return takes. A shareholder can elect for an income payment or a payment intended to be treated as capital for tax purposes depending on his/her/its tax requirements and risk profile. Given that the top rate of personal income tax is to change to 50 per cent from 5 April 2010 whilst the capital gains tax rate is currently to remain at 18 per cent, certain companies which have a significant retail shareholder base may look at returning cash to shareholders in this way. While it is not without risk, it is an option that many companies may wish to consider. How are the B Shares created?

They gave 127m in assets and cash with 40m locked away for decommissioning. Opex and G&A is $33 a barrel and no capex . At 5250 bopd and $65 Brent $5 discount they are making �800k a week. The share return is �22.5m or about 6 months profit. No word on a return to AIM. Future dividend likely. Will we be able to trade the B Shares when they return to AIM?

Hi Velo.... interesting numbers: Mine come in slightly higher for 2017 with revenue at $86.3m and to reach $153m for 2018 is not a big ask .....with a big caveat...at the current poo and an estimated 8000 bopd average. Ive done a couple of graphs with tweets: https://twitter.com/croasdale01/status/953989941888978946 https://twitter.com/croasdale01/status/950850556339392513 The monthly production trendline in the second tweet shows a longer trendline which point to 8000-9000 bopd PROVIDED their is no more lost production due to social unrest etc. S163m revenue is 7000 bopd x 365 x $60. AMER is ahead on bopd and the poo but will they get 365 days of production ... very unlikely .

Jan 129280 Feb 119334 Mar 134681 Apr 145344 May 148544 June 137267 July 60000 approx <----- Lots of social unrest Aug 180800 Sept 120600 <------- social unrest and papal visit Oct 191300 Nov 181500 <------- A few days lost Dec 215000 Jan 220000 estimate The market needs convincing that social unrest 'aka' lost production is not a recurring theme. 3 months out of the last 6 months have had social unrest and lost production. In fact AMER haven't had two consecutive months without social unrest since May/June. Lets get to end of Q1 without lost production and this should be flying a lot higher. Probably $40 million plus revenue and �31m netback - enough for 8 more wells

Q1 2017 �18.9m Q2 2017 �19.5m Q3 2017 �16.3m Q4 2017 �31.9, Q1 2018 Est �40.8m @ $64 and 7000 bopd

https://rockroseenergy.com/ maybe updating?

http://www.birpublications.org/doi/full/10.1259/bjr.20170267 GL all LTH

So much for informed debate: Ill gladly F. O.

What price readmission ? �6 a share ? valuing RRE at �90m

Exactly the answers i was looking for and backed up some of my own research. Botak - thanks for taking the time to get those answers. As you guys couldnt answer my valid questions (seen by some of you as Doubting Thomas - worthy of treason) then it is great that answers have come from the CEO. Ethical? - all science is open to peer review and asking relevant questions - its the very basis of science and plays a large part in investing. Without my valid questions this board would be less well informed. TexRad seems to be more about risk stratification and staging of a known tumour. There are other methods to do this in the field so maybe ask Dr Ganeshan his opinion on DNA Sequencing - competitor or friend - to TexRad or indeed a cell collector , which accumulate patients cells, extracting high concentrations of cancer cells (compared to regular blood sample) - is this a competitor or ally? Shouldnt you guys be doing DD to see if another technology will be a game changer that superseeds TexRad before it takes off - I would do it if invested Did someone mention healthy debate ??

Radiologists are not my colleagues . There is very little real info on the TexRad website so my two fundamental questions : what is the USP and are these other softwares competition - were valid. I had to find the answers myself as always dyor. Maybe you could try it - to improve your poor knowledge and understanding of Tex Rad? I didn’t make derogatory statements or Poo Poo TexRad - and to be sceptical and open minded and not in love with a share is healthy when investing

Botack - if you had taken time to read my last post you would realise that I had softened my sceptic stance and through my own research Now understood how TexRad might make a difference to diagnosis of CT scans and ongoing staging and management of a patient . I had asked open questions to the board effectively asking why I should invest and had very little useful response from anyone other than copy and paste from TexRad website. Of course I was accused of deramping shorting which is always the case when a sceptic coming on to a board of LTH. I am still sceptic that TexRad will even make any real money to justify a £5m to £10m Mcap as there are many barriers to the market the biggest one being the ultra conservative Radiologists reporting the scans. I remain a curious watcher

Meant to say - not a deramper just wanting more info. I don’t I will invest in FDBk but my professional curiosity keeps me looking at this. I asked a PACs specialist who works for Alliance Medical is they had heard of TexRad - they hadn’t .- it doesn’t mean a lot - one person - but they recently integrated software from the OEM I work for into Alliance PACs

Hi Adrianz Yes I’ve done a bit more digging and think I understand what TexRad is useful for. It’s not to detect new lesions or metastasis or detect small lesions that are equivocal in CT or difficult in PETCT. My understanding is that Tecture Analysis potentially adds knowledge to the oncologists confidence of what type or grade of cancer they are dealing with. As such it could change the staging of a patient and the clinical pathway leading to better outcomes ( or more cost effective outcomes) It’s also not integrated in PACS at the moment so is an extra computer system in a busy reporting room. I understand they are working on PACS integration. I can see it’s potential and certainly it has a research niche. Maybe it will be accepted by the radiologist/oncologist community - which is notoriously conservative - maybe not. Alliance Medical use Intelerad PACS and Mirada reporting stations for PETCT. For PETCT - Alliance run about 30 scanners in England ( none in Scotland or Wales)the image workflow is as follows. Patient scanned on mobile or static unit. Images sent to Intelerad PACs in HQ in Warwick. Images then sent to local reporting radiologist Mirada station for review. Report dictated (electronically) and sent to Alliance HQ in Warwick , report also sent to local referrer - oncologist etc. Things to think about: Installation of TexRad either in local PC or PACs or other reporting station on local site. Training of radiologist Team - legal requirement. Semi automated reports to be integrated back into local PACS and Alliance PACs Hope his hel

As to what and why you have invested. I thought there might be someone here who could answer my questions I’ll leave the yes club Bye

Oncology or PACS systems or anything remotely medical. I have no short or shares and don’t intend to buy. Im sure many of you will make a few bob on a spike especially as JW has 4500 followers on Twitter. Good luck. Ps I’ll sleep easy

Oncol